Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 9/20 | 0.33 |
| ▸ | KDM5A | P29375 | 7/20 | 0.33 |
| ▸ | KDM5B | Q9UGL1 | 7/20 | 0.33 |
| ▸ | KDM2B | Q8NHM5 | 4/20 | 0.33 |
| ▸ | KDM4A | O75164 | 3/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6334580 | 0.86 | KDM5A (0.34) | KDM4CKDM5ARAB9AALDH1A1NPC1 | |
| SCHEMBL6327267 | 0.82 | SMN1; SMN2 (0.33) | KDM4CKDM5AKDM5BRAB9AALDH1A1 | |
| SCHEMBL6333530 | 0.80 | MEN1 (0.32) | KDM4CKDM5AKDM5BRAB9AALDH1A1 | |
| SCHEMBL6326674 | 0.76 | MEN1 (0.30) | RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL6408428 | 0.75 | — | — | |
| SCHEMBL6327440 | 0.75 | KDM4C (0.33) | KDM4CKDM5AKDM5BTP53MAPT | |
| SCHEMBL6331247 | 0.73 | MAPT (0.32) | ALDH1A1KMT2AMAPTHPGDMEN1 | |
| SCHEMBL6858814 | 0.72 | — | — | |
| SCHEMBL6333418 | 0.72 | — | — | |
| SCHEMBL6326586 | 0.71 | KDM4E (0.32) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936570-B2 | Tetrazolinone derivatives | NIHON BAYER AGROCHEM, K.K. (JP) | 2005-08-30 | — | — | US | disclosed |
| US-20040242895-A1 | Novel tetrazolinone derivatives | YANAGI AKIHIKO (JP) | 2004-12-02 | — | — | US | disclosed |
| US-6790810-B2 | Tetrazolinone derivatives | NIHON BAYER AGROCHEM K.K. (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20040102635-A1 | Novel tetrazolinone derivatives | YANAGI AKIHIKO (JP) | 2004-05-27 | — | — | US | disclosed |
| US-6624121-B1 | Exemplified by 2-cyano-3-cyclopropyl-1-(3-((4-cyclopropyl-4,5-dihydro-5-oxo-1H-tetrazol-1 -yl)methyl)-2, 4-dichlorophenyl)propan-1,3-dione | NIHON BAYER AGROCHEM K.K. (JP) | 2003-09-23 | — | — | US | disclosed |
| EP-1208090-A1 | HERBICIDALTETRAZOLINONE DERIVATIVES | NIHON BAYER AGROCHEM K.K. (JP) | 2002-05-29 | — | — | EP | disclosed |
| WO-2001010850-A1 | HERBICIDAL TETRAZOLINONE DERIVATIVES | NIHON BAYER AGROCHEM K.K. (DE) | 2001-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102635-A1 | Novel tetrazolinone derivatives | CBR1, CBR3, CYP1B1 | KDM4C 834/4885KDM5A 2397/4885KDM5B 3097/4885 |
| US-20040242895-A1 | Novel tetrazolinone derivatives | CBR3, CBR1, CYP1B1 | KDM4C 886/4885KDM5A 2426/4885KDM5B 3094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.